Protagonist Therapeutics(PTGX) ZACKS·2025-03-12 17:01Core Viewpoint - Protagonist Therapeutics (PTGX) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Protagonist Therapeutics suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [7][9]. - Protagonist Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - Protagonist Therapeutics is projected to earn -$1.23 per share for the fiscal year ending December 2025, reflecting a year-over-year change of -129.1% [8]. - Over the past three months, the Zacks Consensus Estimate for Protagonist Therapeutics has increased by 11.2%, indicating a positive revision trend [8].